Article Contents ::

Details About Generic Salt ::  Nilutami

Main Medicine Class::    

(nye-LOO-tah-mide)
Nilandron
Tablets
50 mg.
Class: Antiandrogen

 Indications Metastatic prostate cancer in combination with surgical castration.

 Contraindications Severe hepatic impairment; severe respiratory insufficiency; hypersensitivity to nilutamide or any component of this preparation.

 Route/Dosage

Prostate Cancer

ADULTS: PO Initial dose: 300 mg (6 tablets) PO once daily for 30 days. Maintenance dose: 150 mg (3 tablets) PO once daily.

Interactions Inhibits hepatic cytochrome P450 enzymes. May alter the elimination of other agents metabolized by the cytochrome P450 system. Monitor patients for increased serum levels and toxicity during concomitant therapy with warfarin, phenytoin, or theophylline.

Lab Test Interferences Increased ALT and AST.

 Adverse Reactions

CARDIOVASCULAR: Peripheral edema, hypertension, chest pain; heart failure. CNS: Insomnia; headache; dizziness; depression; hypesthesia; asthenia; paresthesia. DERMATOLOGIC: Sweating; loss of body hair; dry skin. ENDOCRINE: Hot flashes. GI: Low potential for nausea and vomiting; constipation; anorexia; abdominal pain; hemorrhage or melena (2%). GU: Testicular atrophy; urinary tract infection. HEMATOLOGIC: Anemia. METABOLIC: Alcohol intolerance. MUSCULOSKELETAL: Pain; bone pain. RESPIRATORY: Dyspnea; pneumonia; intestinal pneumonitis. SPECIALSENSES: Delayed adjustment to dark or light; abnormal vision; cataract. OTHER: Flu-like syndrome.

 Precautions

Pregnancy: Category C. Children: Safety and efficacy in pediatric patients have not been established. Hepatitis: Severe liver injury has been reported. Hepatotoxicity in these reports generally occurred within the first 3 to 4 mo of treatment. Women: Nilutamide has no indication for women. Delay in adaptation to the dark: When passing from a lighted area to a dark area.

PATIENT CARE CONSIDERATIONS


 Administration/Storage

  • Store at room temperature; protect from light.
  • Initiate therapy on day of surgical castration or the day after surgery. Nilutamide may be taken without regard to meals.

 Assessment/Interventions

  • Monitor LFTs at baseline and at 3-mo intervals during therapy.
  • Measure serum transaminase levels prior to starting treatment and at regular intervals for the first 4 mo of treatment and periodically thereafter. Obtain LFTs at the first sign or symptoms suggestive of liver dysfunction (eg, nausea, vomiting, abdominal pain, fatigue, anorexia, flu-like symptoms, dark urine, jaundice, right upper quadrant tenderness).
  • Perform a routine chest x-ray prior to initiating treatment. Baseline pulmonary function tests may be considered.
  • If at any time, a patient has jaundice or their ALT rises > 2 times the upper limit of normal, discontinue nilutamide with close follow up of LFTs until resolution.
OVERDOSAGE: SIGNS & SYMPTOMS
  GI disorders, including nausea and vomiting, malaise, headache, dizziness (600 and 900 mg/day)

 Patient/Family Education

  • Start nilutamide tablets on the day of, or the day after, surgical castration. Patients should not interrupt their dosing of nilutamide or stop taking the medication without consulting their health care provider.
  • Delays of visual adaptation from light to dark may occur. Advise patients to use caution when driving at night or through tunnels. Patients can use tinted glasses to help decrease the problem.
  • Nilutamide may cause alcohol-intolerance. Avoid alcohol if facial flushing, malaise, or hypotension occurs after consuming alcoholic beverages.
  • Notify your doctor at the first sign or symptoms suggestive of liver dysfunction (eg, nausea, vomiting, abdominal pain, fatigue, anorexia, flu-like symptoms, dark urine, jaundice, right upper quadrant tenderness).
  • Tell health care provider immediately of any dyspnea or agggravation of preexisting dyspnea.
  • Instruct patients to report any new or worsening shortness of breath that they experience while on nilutamide. If symptoms occur, discontinue nilutamide immediately until it can be determined if the symptoms are drug-related.

Medicscientist Drug Facts

 

Drugs Class ::

(nye-LOO-tah-mide)
Nilandron
Tablets
50 mg.
Class: Antiandrogen

Indications for Drugs ::

 Indications Metastatic prostate cancer in combination with surgical castration.

Drug Dose ::

 Route/Dosage

Prostate Cancer

ADULTS: PO Initial dose: 300 mg (6 tablets) PO once daily for 30 days. Maintenance dose: 150 mg (3 tablets) PO once daily.

Contraindication ::

 Contraindications Severe hepatic impairment; severe respiratory insufficiency; hypersensitivity to nilutamide or any component of this preparation.

Drug Precautions ::

 Precautions

Pregnancy: Category C. Children: Safety and efficacy in pediatric patients have not been established. Hepatitis: Severe liver injury has been reported. Hepatotoxicity in these reports generally occurred within the first 3 to 4 mo of treatment. Women: Nilutamide has no indication for women. Delay in adaptation to the dark: When passing from a lighted area to a dark area.

PATIENT CARE CONSIDERATIONS


Drug Side Effects ::

 Adverse Reactions

CARDIOVASCULAR: Peripheral edema, hypertension, chest pain; heart failure. CNS: Insomnia; headache; dizziness; depression; hypesthesia; asthenia; paresthesia. DERMATOLOGIC: Sweating; loss of body hair; dry skin. ENDOCRINE: Hot flashes. GI: Low potential for nausea and vomiting; constipation; anorexia; abdominal pain; hemorrhage or melena (2%). GU: Testicular atrophy; urinary tract infection. HEMATOLOGIC: Anemia. METABOLIC: Alcohol intolerance. MUSCULOSKELETAL: Pain; bone pain. RESPIRATORY: Dyspnea; pneumonia; intestinal pneumonitis. SPECIALSENSES: Delayed adjustment to dark or light; abnormal vision; cataract. OTHER: Flu-like syndrome.

Drug Mode of Action ::  

(nye-LOO-tah-mide)
Nilandron
Tablets
50 mg.
Class: Antiandrogen

Drug Interactions ::

Interactions Inhibits hepatic cytochrome P450 enzymes. May alter the elimination of other agents metabolized by the cytochrome P450 system. Monitor patients for increased serum levels and toxicity during concomitant therapy with warfarin, phenytoin, or theophylline.

Drug Assesment ::

 Assessment/Interventions

  • Monitor LFTs at baseline and at 3-mo intervals during therapy.
  • Measure serum transaminase levels prior to starting treatment and at regular intervals for the first 4 mo of treatment and periodically thereafter. Obtain LFTs at the first sign or symptoms suggestive of liver dysfunction (eg, nausea, vomiting, abdominal pain, fatigue, anorexia, flu-like symptoms, dark urine, jaundice, right upper quadrant tenderness).
  • Perform a routine chest x-ray prior to initiating treatment. Baseline pulmonary function tests may be considered.
  • If at any time, a patient has jaundice or their ALT rises > 2 times the upper limit of normal, discontinue nilutamide with close follow up of LFTs until resolution.
OVERDOSAGE: SIGNS & SYMPTOMS
  GI disorders, including nausea and vomiting, malaise, headache, dizziness (600 and 900 mg/day)

Drug Storage/Management ::

 Administration/Storage

  • Store at room temperature; protect from light.
  • Initiate therapy on day of surgical castration or the day after surgery. Nilutamide may be taken without regard to meals.

Drug Notes ::

 Patient/Family Education

  • Start nilutamide tablets on the day of, or the day after, surgical castration. Patients should not interrupt their dosing of nilutamide or stop taking the medication without consulting their health care provider.
  • Delays of visual adaptation from light to dark may occur. Advise patients to use caution when driving at night or through tunnels. Patients can use tinted glasses to help decrease the problem.
  • Nilutamide may cause alcohol-intolerance. Avoid alcohol if facial flushing, malaise, or hypotension occurs after consuming alcoholic beverages.
  • Notify your doctor at the first sign or symptoms suggestive of liver dysfunction (eg, nausea, vomiting, abdominal pain, fatigue, anorexia, flu-like symptoms, dark urine, jaundice, right upper quadrant tenderness).
  • Tell health care provider immediately of any dyspnea or agggravation of preexisting dyspnea.
  • Instruct patients to report any new or worsening shortness of breath that they experience while on nilutamide. If symptoms occur, discontinue nilutamide immediately until it can be determined if the symptoms are drug-related.

Medicscientist Drug Facts

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.

We would like to keep you updated with special notifications.